ArticleJournal of advanced pharmaceutical technology & research
Cytotoxic effect and apoptotic induction of tricyclohexyltin p-methoxycinnamate on HT-29 colorectal cancer cells: Implications for anticancer therapeutics.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer's escalating prevalence in Malaysia prompts the exploration of innovative anticancer agents; amidst this backdrop, tricyclohexyltin p-methoxycinnamate emerges as a synthesized organotin complex with unique bioactive properties. Notably, the novelty of this research lies in its groundbreaking investigation into the hitherto unexplored anticancer potential and mode of cell death induced by tricyclohexyltin p-methoxycinnamate on colon cancer (human colorectal adenocarcinoma cell line (HT-29)) cell lines. This study pioneers the assessment of tricyclohexyltin p-methoxycinnamate's cytotoxic effects through the "(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay," revealing a dose- and time-dependent cytotoxicity with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.